Nasdaq

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

BOSTON, Jan. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced a ...
Investing

TransCode and Quantum Leap to test cancer therapy in phase 2a trial

BOSTON - TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a micro-cap biotech company with a market capitalization of just $7.91 million, and Quantum Leap Healthcare Collaborative announced Thursday a ...
Nasdaq

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

BOSTON, Dec. 11, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) and Quantum Leap Healthcare Collaborative ("Quantum Leap") today announce a new collaboration to evaluate TransCode's ...